In a significant move to bolster the cell and gene therapy (CGT) sector, China-based biotechnology firms uBriGene, Fraserna, and Virogin have entered into a strategic partnership agreement. While the financial details of the agreement remain undisclosed, the collaboration is poised to integrate the global resources of the three companies, offering a comprehensive suite of services to the CGT industry.
Leveraging Expertise for Comprehensive CGT Services
The partnership aims to leverage uBriGene’s extensive Contract Development and Manufacturing Organization (CDMO) experience in CGT drug process development and Good Manufacturing Practice (GMP) production. This expertise will be combined with Fraserna’s professional service capabilities in early research and clinical research, and Virogin’s substantial clinical experience in generating oncolytic viruses and mRNA-based tumor immunotherapy. Together, they will provide a full-process solution for innovative CGT developers.
Accelerating Global Marketing of CGT Drugs
The collaborative effort will support early research and offer a seamless solution from process development, registration, and application to clinical trials and commercial production. This integrated approach is designed to accelerate the global marketing process for CGT drugs, facilitating faster access to potentially life-changing therapies for patients worldwide.-Fineline Info & Tech
